A 20 percent weight loss means 20 pounds for every 100 pounds of starting weight. At 200 pounds, it is 40 pounds. At 250 pounds, it is 50. In SURMOUNT-1, the tirzepatide 15 mg group averaged 20.9% weight loss over 72 weeks, but that average was not everybody's result: about 57 in 100 participants lost at least 20%. The useful question is not only what moved on the scale, but what happened to waist measurements, blood-pressure readings and lab numbers in that trial.
What 20 percent weight loss means in pounds
The calculation is starting weight multiplied by 0.20. The result scales with the starting point.
| Starting weight | 20% of that weight | 80% remaining |
|---|---|---|
| 150 lb | 30 lb | 120 lb |
| 200 lb | 40 lb | 160 lb |
| 250 lb | 50 lb | 200 lb |
| 350 lb | 70 lb | 280 lb |
These are arithmetic examples, not expected outcomes. The 15 percent weight-loss numbers page shows the same idea at a different landmark without turning either percentage into a goal everyone should reach.
The trial figure needs the same restraint. SURMOUNT-1 enrolled adults with obesity, or overweight plus a related health condition, and excluded people with diabetes. Everyone received nutrition and activity support. The 20.9% number describes the average for one assigned dose group under that study's conditions.
The two trials behind the 20 percent figure
Two large studies produced numbers near 20%, but they did not ask exactly the same question.
| Trial | People studied | Time | Headline result | How many reached at least 20% |
|---|---|---|---|---|
| SURMOUNT-1, tirzepatide 15 mg | 2,539 adults overall; no diabetes | 72 weeks | −20.9% average in the assigned group | 56.7% in the 15 mg group |
| STEP UP, semaglutide 7.2 mg | 1,407 adults; no diabetes | 72 weeks | −20.7% assuming planned treatment was followed | 50.9% in that analysis |
The SURMOUNT-1 paper in the New England Journal of Medicine reported 20.9% for the 15 mg group versus 3.1% for placebo in an analysis that kept people in their assigned groups regardless of whether treatment stopped. Its full design and side-effect tables belong in the SURMOUNT-1 results guide.
STEP UP needs an extra line of explanation. An estimand is the exact question a trial's analysis is designed to answer. In the analysis that assumed participants stayed on the planned treatment, average loss was 20.7%; in the main analysis that counted results regardless of adherence, it was 18.7% with semaglutide 7.2 mg, 15.6% with 2.4 mg and 3.9% with placebo. The peer-reviewed STEP UP paper reports that second set clearly.
That difference is not fine print. It is why 20.7% and 20.9% should not be treated as a head-to-head ranking. The trials used different medicines, protocols and analysis plans. Neither number predicts what one person will lose, and the doses are study facts rather than instructions. A prescriber sets the actual dose.
What changed besides weight in SURMOUNT-1
The scale was only one measurement. These figures compare the 15 mg tirzepatide group with placebo at week 72 unless the row says otherwise. They are group averages, not a package of changes that every participant experienced.
| Measure | Tirzepatide result | Placebo result | What it looks like on a record |
|---|---|---|---|
| Waist circumference | −18.5 cm | −4.0 cm | About 7.3 inches versus 1.6 inches |
| Systolic blood pressure | −7.6 mm Hg | −1.2 mm Hg | About eight points versus one on the top number |
| Diastolic blood pressure | −4.6 mm Hg | −1.0 mm Hg | About five points versus one on the bottom number |
| Fasting insulin | −45.3% | −6.6% | A lower fasting result, reported as a percent change |
| Triglycerides | −31.4% | −6.3% | A larger drop in this blood fat |
| LDL cholesterol | −8.6% | −0.9% | A modest average drop in LDL |
| HDL cholesterol | +8.2% | +0.2% | A rise in HDL |
| HbA1c | −0.51 percentage points | −0.07 points | A shift in average blood sugar over two to three months |
A centimeter result cannot be translated into a clothing size. Bodies change in different places, and clothing brands do not use one standard. The blood-pressure figures also need context: the starting averages were about 123/80 mm Hg. A later analysis found that pooled tirzepatide groups ended 6.8 systolic points and 4.2 diastolic points lower than placebo, while low-blood-pressure events remained uncommon. The blood-pressure analysis in Heart also estimated that weight change explained most, but not all, of that difference.
About 41% of SURMOUNT-1 participants began with prediabetes. By week 72, 95.3% of those assigned to tirzepatide had returned to normal blood-sugar measures, compared with 61.9% on placebo. That is a group result in people selected for the trial, not a guarantee that a particular HbA1c will cross a cutoff.
Fresh data adds a risk estimate, not an event count
As of September 18, 2026, the day this article was written, an analysis published August 10, 2026 had followed the SURMOUNT-1 prediabetes group into the three-year period. Among 962 participants with enough data and no existing cardiovascular disease, the model-estimated 10-year cardiovascular risk fell by 1.92 percentage points at week 72 in the 15 mg group, while it rose by 1.10 points with placebo.
The distinction matters: researchers calculated that estimate from a risk equation. They did not count enough heart attacks and strokes to show that exact reduction. The authors said an outcomes trial is still needed to test it. That careful limit appears in the 2026 European Journal of Preventive Cardiology paper.
What 20 percent weight loss cannot tell you
A percentage cannot choose a medicine, predict side effects or say how much any one health marker will move. It also does not erase the value of earlier changes; the evidence around 5 percent weight loss answers that smaller-landmark question separately.
Both trials studied branded products under controlled research protocols. They did not test Promise's compounded formulations. Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The compounded formulation is not the branded product the FDA approved in its November 8, 2023 letter for Zepbound. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and doctor.
STEP UP's 7.2 mg result also came from branded semaglutide. That branded result does not turn the trial average into evidence for a different formulation.
Put the percentage beside the rest of the record
Twenty percent is most useful when it sits beside the starting weight, waist measurement, blood pressure, HbA1c, fasting lipids, current medicines and side effects. It is a research landmark, not a pass-or-fail line.
At Promise, a licensed provider reviews every request and not everyone qualifies. The review decides whether treatment fits and which measurements make sense to follow.
